Transforming Care With Patient-Centered focus

Love Lifesciences is advancing care through responsible innovation— learning fast, acting ethically, and delivering solutions that genuinely improve patient lives.

Because Every Dose Matters

Mission: Revolutionize the patient experience to ensure all patients are given the opportunity to Love Life

Our Story

2021

Love Lifesciences founded by Nick Love, MD, MBA and Bradley Hopper after witnessing patient non-compliance

2022

Prototype UNIPEN developed;

UNIPEN patents & trademarks filed

2023

ISO, FDA Guidance & Human Factors testing performed on UNIPEN;

Commercial strategy developed & initiated

2024

FDA determination letter received;

APC strategic partnership announced

2025

UniPen Limited Market Release (LMR) launched; 

Semi-Automated Tabletop Fill-Finish System developed, patents filed & launched with LMR partner 

2026

Official Full Market Launch of UniPen and Tabletop Fill-Finish System

Love Lifesciences' Guiding Pillars

Patient Centric – Every decision starts with the patient, ensuring Love Lifesciences’ products measurably enhance their experience and outcomes.

Adapt and Pivot – Agility is in the Love Lifesciences DNA, enabling our team to seize new opportunities and outmaneuver entrenched competitors.

Ethical Business Practices– We conduct all operations with uncompromising integrity, honoring the trust of patients, colleagues, and investors alike.

Rapidly Learn from Success & Failure [Always Learn, Rapidly] – We grow faster by rigorously extracting lessons from every win, misstep, and shared experience.

Exceed the Standard – Meeting regulations is the baseline; we intentionally outperform industry benchmarks to deliver superior outcomes and exceptional value.

Innovate in Every Aspect – We embed creative problem-solving across product & business so each challenge results in breakthroughs that amplify impact.

CORE TEAM

Nick Love, MD, MBA

CEO, Co-Founder

  • Background in Biopharma Business Analytics & Research
  • Board Member – BioKansas
  • Advisory Board Member – KU School of Medicine

Bradley Hopper

CTO, Co-Founder

  • 10y+ founding & growing companies  in various industries
  • Background in Product Design 
&  Engineering

Erik Blume, JD, MBA

Chief Operations Officer

  • 10y+ founding, building, and supporting biosciences and 
deep-tech startups

Sujal Shah

Head of Growth Strategy

  • 20y+ in MedTech commercial 
& market development strategy leadership for Johnson & Johnson, Pfizer

John Ziobro

Head of Regulatory Affairs

  • 35y+ Medical Device expertise including executive management, engineering, regulatory affairs

Richard Hollocher

Lead Engineer

  • Experienced mechanical engineer with a background at Honeywell FM&T and Spirit Aerosystems

Clinical & Scientific Advisory Board

Kyle Gillett, MD

  • Founder of Gillett Health Medical Spa & Concierge Care
  • Specializes in Obesity Medicine & Hormone Replacement Therapy

Brian Williamson, PharmD

  • Previous Founder & Owner of JCB Laboratories, 503B Pharmacy sold to Fagron

Rick Couldry, PharmD

  • Chief Pharmacy Officer / VP of Health Professions at The University of Kansas Health System
  • Built >$500M ARR Specialty Pharmacy

Selina Gierer, DO

  • Director of Allergy & Immunology at the University of Kansas Health System

Dan Aires, MD, JD

  • Prior Director of Division in Dermatology at The University of Kansas Hospital System
  • CEO & Co-Founder of Kanpecia Biotech

Tom Krol, PharmD

  • 30y+ Experience in Pharma/Biotech including strategy development, drug development

Lisa Friis, PhD

  • Director of Product Development Core at KU
  • CTO DirectSync Surgical

COMMERCIAL ADVISORY BOARD

Nancy Forlenza

  • 20y+ in Pharma Sales Management including startup experience
  • Launched & sold injectable products including TRT

Jason Andrews

  • CEO at GemTech Manufacturing
  • Prior Owner/CEO of GroupSource GPO
  • 20y+ in medical device sales

Bryce Davis

  • CEO at Data Insights
  • CEO at Karte Payments & Managing Partner PayCloud innovations

Dave Van Brunt

  • 25y+ Experience as Marketing Director & VP of Marketing at GSK and Bayer

Kevin Lockett

  • Board Member – The  University of Kansas Health System and Kansas City University
  • Managing Partner, Fulcrum Global Capital

Robin Love

  • 20y+ in Pharma/Medical  Device Sales Management at J&J, Pfizer, and Novartis
  • Launched & sold multiple injectable products

backed by a growing Network of more than 130 trusted partners, customers, and supporting organizations